L-CYSTEINAMIDE, D-PHENYLALANYL-L-CYSTEINYL-L-PHENYLALANYL-D-TRYPTOPHYL-L-LYSYL-L-THREONYL-N-(2-HYDROXY-1-(HYDROXYMETHYL)PROPYL)-, CYCLIC (2->7)-DISULFIDE, (R-(R,R))-

Digestive System Neuroendocrine Neoplasm

Novartis Pharmaceuticalsprotein_peptidePhase 3Active

66/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 51/ 100
Competitive Position: 95/ 100

Competitive context

21 Active assets in the Digestive System Neuroendocrine Neoplasm cohort.

Asset / Sponsor	Phase	Rating
Oxodotreotide National Cancer Institute (NCI)	Phase 4	BBB
EUDEMINE INJECTION University of Maryland, Baltimore	Phase 4	BB
Everolimus RayzeBio, Inc.	Phase 3	BB
Edotreotide Jiangsu HengRui Medicine Co., Ltd.	Phase 3	B
Regorafenib Translational Research in Oncology	Phase 2	B

View all 31 →

Same molecule, other indications

L-CYSTEINAMIDE, D-PHENYLALANYL-L-CYSTEINYL-L-PHENYLALANYL-D-TRYPTOPHYL-L-LYSYL-L-THREONYL-N-(2-HYDROXY-1-(HYDROXYMETHYL)PROPYL)-, CYCLIC (2->7)-DISULFIDE, (R-(R*,R*))- is also rated in:

esophageal varicesDormant

Indicative · Phase 4

71 / 100

View asset →

diarrheal diseaseDormant

Indicative · Phase 3

71 / 100

View asset →

cirrhosis of liverDormant

Indicative · Phase 4

71 / 100

View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →